Trial Profile

Eftilagimod Alpha in Combination With Neoadjuvant Chemotherapy in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eftilagimod alpha (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
Indications Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use

Most Recent Events

11 Jun 2026 Planned initiation date changed from 1 May 2026 to 1 Sep 2026.
20 Feb 2026 Planned initiation date changed from 2 Jan 2026 to 1 May 2026.
10 Dec 2025 Planned initiation date changed from 1 Nov 2025 to 2 Jan 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com